This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Svensson, P. Articles by Östergren, J. Search for Related Content PubMed PubMed Citation Articles by Svensson, P. Articles by Östergren, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Peripheral Arterial Disease Related Collections Cardiovascular Pharmacology Secondary prevention Peripheral vascular disease Clinical Studies

(Hypertension. 2001;38:e28.)
© 2001 American Heart Association, Inc.

Hypertension Electronic Pages

Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures

A HOPE Substudy

Per Svensson; Ulf de Faire; Peter Sleight; Salim Yusuf; Jan Östergren

Department of Medicine Karolinska Hospital (P.S., U.d.F., J.Ö.), Stockholm, Sweden; The John Radcliffe Infirmary (P.S.), Oxford, United Kingdom; and McMaster University (S.Y.), Hamilton, Ontario, Canada.

Correspondence to Per Svensson, MD, Department of Medicine, Division of Emergency and Cardiovascular Medicine, Karolinska Hospital, S-171 76 Stockholm, Sweden. E-mail persv{at}divmed.ks.se

Abstract

In the HOPE-trial, the ACE inhibitor ramipril significantly reduced cardiovascular morbidity and mortality in patients at high risk for cardiovascular events. The benefit could only partly be attributed to the modest mean reduction of office blood pressure (OBP) during the study period (3/2 mm Hg). However, because according to the HOPE protocol ramipril was given once daily at bedtime and blood pressure was measured during the day, the 24-hour reduction of blood pressure may be underestimated based on OBP. Thirty-eight patients with peripheral arterial disease enrolled in the HOPE study underwent 24-hour ambulatory blood pressure (ABP) measurement before randomization and after 1 year. OBP was measured in the sitting position immediately before fitting the ABP measuring equipment to the patients. Ramipril did not significantly reduce OBP (8/2 mm Hg, P=NS) or day ABP (6/2 mm Hg, P=NS) after 1 year. Twenty-four–hour ABP was significantly reduced (10/4 mm Hg, P=0.03), mainly because of a more pronounced blood pressure lowering effect during nighttime (17/8 mm Hg, P<0.001). The night/day ratio was also significantly lowered in the ramipril group. ABP shows greater falls, especially at night, than OBP during treatment with ramipril given once daily at bedtime. Although, OBP is the correct comparator when comparing with previous large intervention trials and epidemiological studies, the effects on cardiovascular morbidity and mortality seen with ramipril in the HOPE study may, to a larger extent than previously ascribed, relate to effects on blood pressure patterns over the 24-hour period.

Key Words: antihypertensive therapy • blood pressure monitoring • ambulatory • clinical trials • peripheral vascular diseases • angiotensin-converting enzyme inhibitors • ramipril

This article has been cited by other articles:

				B. R. Davis, L. B. Piller, K. Dunn, J. A. Cutler, M. Proschan, C. Furberg, D. Goff, S. Franklin, F. Leenen, S. Mohiuddin, et al. Response to Letter Regarding Article, "Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)" Circulation, January 16, 2007; 115(2): e19 - e19. [Full Text] [PDF]

				F. D. Fuchs It is time to stop comparing blood pressure-lowering drugs with placebo. Arch Intern Med, September 18, 2006; 166(16): 1786 - 1786. [Full Text] [PDF]

				S. I. Sokol, E. L. Portnay, J. P. Curtis, M. A. Nelson, P. R. Hebert, J. F. Setaro, and J. M. Foody Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke Neurology, July 27, 2004; 63(2): 208 - 213. [Abstract] [Full Text] [PDF]

				P. Rashid, J. Leonardi-Bee, and P. Bath Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review Stroke, November 1, 2003; 34(11): 2741 - 2748. [Abstract] [Full Text] [PDF]

				J Bosch and S Yusuf Conundrum of the HOPE study: Authors' reply BMJ, September 20, 2003; 327(7416): 682 - 682. [Full Text]

				R. Taylor Conundrum of the HOPE study: Time of taking ramipril may account for lack of relation between blood pressure and outcome BMJ, September 20, 2003; 327(7416): 681 - 682. [Full Text]

				R. C. Hermida, C. Calvo, D. E. Ayala, J. E. Lopez, J. R. Fernandez, A. Mojon, M. J. Dominguez, and M. Covelo Seasonal Variation of Fibrinogen in Dipper and Nondipper Hypertensive Patients Circulation, September 2, 2003; 108(9): 1101 - 1106. [Abstract] [Full Text] [PDF]

				T. G. Pickering, L. H. Krut, A. M. Reese, R. L. Talbert, H. I. Bussey, V. L.M. Esnault, B. R. Davis, J. T. Wright Jr., J. A. Cutler, L. M.H. Wing, et al. Angiotensin-Converting-Enzyme Inhibitors and Diuretics for Hypertension N. Engl. J. Med., July 3, 2003; 349(1): 90 - 93. [Full Text] [PDF]

				M. J Brown A RATIONAL BASIS FOR SELECTION AMONG DRUGS OF THE SAME CLASS Heart, June 1, 2003; 89(6): 687 - 694. [Full Text] [PDF]

				P. Bath Blood Pressure-Lowering for Secondary Prevention of Stroke: ACE Inhibition Is Not the Key Stroke, May 1, 2003; 34(5): 1334 - 1335. [Full Text] [PDF]

				G. D. Moutsatsos More Hype Than HOPE Hypertension, April 1, 2003; e4(4): . [Full Text] [PDF]

				G. J. Hankey Angiotensin-Converting Enzyme Inhibitors for Stroke Prevention: Is There HOPE for PROGRESS After LIFE? Stroke, February 1, 2003; 34(2): 354 - 356. [Full Text] [PDF]

				L. B. Goldstein Prevention and Health Services Delivery Stroke, February 1, 2003; 34(2): 367 - 369. [Full Text] [PDF]

				P Badrinath, A. P Wakeman, J. G Wakeman, J. S Yudkin, M. S Parmar, and B. Twisselmann Preventing stroke with ramipril BMJ, August 24, 2002; 325(7361): 439 - 439. [Full Text] [PDF]